Senate Community Affairs Legislation Committee [Part 2]

Senate Estimates hearing,

Searchable transcript of the Senate Community Affairs Legislation Committee [Part 2], 28 Oct 2026 Senate Estimates hearing, with chapters: Medicare Application for Gender Affirmation Surgeries, Medical Terminology and Gender Incongruence Definitions, Access to IBD Treatments for Children, Private…

Chapters

  1. Medicare Application for Gender Affirmation Surgeries (54:47)

    Senator Roberts questions the department regarding an application by plastic surgeons to list gender affirmation surgeries on Medicare, focusing on potential taxpayer costs and the early stage of the assessment process.

  2. Medical Terminology and Gender Incongruence Definitions (58:53)

    Officials explain the definitions of gender incongruence and gender dysphoria as established by the World Health Organization and discuss how these terms are applied in medical and legal contexts.

  3. Access to IBD Treatments for Children (1:04:43)

    Senator Ruston discusses the process for approving specialist discretion pathways for first-line biologics therapy for children with Inflammatory Bowel Disease (IBD) and the timeliness of PBAC assessments.

  4. Private Health Insurance Rebate and FOI (1:09:28)

    The committee examines freedom of information documents regarding proposed changes to private health insurance rebates and their potential impact on public hospital demand.

  5. Modeling Health Insurance Downgrade Behavior (1:14:10)

    Senator Ruston questions the department on its modeling of policy impacts, specifically regarding the number of individuals expected to downgrade their health insurance coverage.

  6. Impact on Public Hospital Patient Days (1:16:34)

    Discussion focuses on the projected increase in public hospital patient days and the resulting financial burden on state and territory health systems due to federal insurance changes.

  7. FOI Review and Public Interest Immunity (1:19:29)

    The department explains the ongoing review process for FOI requests and addresses the availability of specific data regarding hospital demand projections for future years.

  8. PBS Safety Net and Medicine Affordability (1:23:24)

    Senator Stewart inquires about budget measures to lower medicine costs, focusing on how the PBS safety net threshold works for general and concessional patients.

  9. 60-Day Prescriptions and Pharmacy Viability (1:27:11)

    Officials provide updates on the uptake of 60-day prescriptions and the financial support provided to pharmacies under the 8th Community Pharmacy Agreement to ensure sector viability during the transition.

  10. Dose Administration Aids and Pharmacy Caps (1:31:06)

    The committee examines the funding of Dose Administration Aids (DAAs) and the interaction between pharmacy caps and the Support at Home program for older Australians.

  11. HTA Review and Industry Negotiations (1:39:06)

    Discussion on the status of the Health Technology Assessment (HTA) review final report and upcoming strategic agreement negotiations with the medicines industry peak bodies.

  12. Private Health Insurance Rebate Compliance (1:44:48)

    Senator Ruston questions how the Private Health Insurance (PHI) rebate is monitored and enforced, focusing on the roles of Services Australia and the ATO in reconciling income tiers.

  13. PHI Rebate Bill and Pensioner Carve-outs (1:50:02)

    A heated debate occurs regarding proposed amendments to the PHI rebate bill, specifically concerning a carve-out for age pensioners and the government's approach to legislative negotiations.

  14. Newborn Bloodspot Screening and Pompe Disease (1:58:37)

    The committee reviews the progress of expanding newborn bloodspot screening to 80 conditions, with specific focus on the MSAC recommendation regarding Pompe disease.

  15. Strategic Agreements and HTA Review Implementation (2:04:06)

    Officials discuss negotiations for new strategic agreements with Medicines Australia and GBMA, focusing on HTA review recommendations and PBS listing timelines.

  16. Medicare Assignment of Benefits Verbal Consent (2:08:37)

    Examination of the transition period for Medicare assignment of benefits (AOB) and the decision to maintain verbal consent options for clinicians.

  17. Private Health Insurance Rebate and Premiums (2:14:46)

    Discussion on the legislative timing for private health insurance rebate changes and the impact on the April 1st premium round.

  18. PBAC Pricing Recommendations and Cost Effectiveness (2:21:43)

    An overview of how the Pharmaceutical Benefits Advisory Committee (PBAC) determines cost-effective pricing and provides guidance to sponsors.

  19. Review of Multiple Sclerosis Medicines Listings (2:26:04)

    Details on the rapid review of relapsing-remitting multiple sclerosis medicines and the impact of pricing policies on PBS listings.

  20. HTA Review Final Report and Briefings (2:30:53)

    Discussion regarding the final report of the Health Technology Assessment (HTA) review and briefings provided to PBAC chairs.

  21. Committee Suspension and Outcome Transition (2:32:21)

    The committee takes a short suspension before reconvening for Outcome 1.

  22. Prostate Cancer Nurse Funding Transition (2:47:42)

    Discussion regarding the decision to redirect funding for prostate cancer nurses from the Prostate Cancer Foundation of Australia to the McGrath Foundation, focusing on the rationale of the Australian Cancer Plan and streamlining service delivery.

  23. Declining Gardasil Vaccination Rates in Australia (2:58:19)

    Examination of declining Gardasil vaccination rates for both males and females in recent years and the potential long-term health implications for cervical cancer eradication.

  24. National Mental Health Agreement Status Update (3:00:28)

    An update on the status of negotiations for a replacement National Mental Health and Suicide Prevention Agreement and the continuation of funding bilaterals beyond 2027.

  25. Psychosocial Support Access and Unmet Need (3:03:08)

    Analysis of the unmet need for psychosocial support services across Australia and the current level of Commonwealth funding compared to sector assessments of service shortfalls.

  26. Suicide Prevention Program Funding and Extensions (3:07:20)

    Details on the $82.9 million funding extension for the National Suicide Prevention Leadership and Support Program and how this investment builds on previous commitments.

  27. Childhood Vaccine Safety and Adverse Events (3:09:32)

    Inquiry into adverse event reporting discrepancies for childhood vaccines and scientific research regarding vaccine ingredients, such as aluminium adjuvants, and their potential neurological effects.

  28. COVID-19 Vaccination Advice for Pregnant Women (3:18:31)

    Questioning of ATAGI regarding the scientific evidence and safety data used to recommend COVID-19 vaccination for pregnant women at various stages of the pandemic.

  29. Effectiveness of Suicide Prevention Investment (3:23:24)

    Review of the effectiveness of the $610 million government investment in suicide prevention in light of findings from the Auditor-General and the Productivity Commission.

  30. National Suicide Prevention Strategy Implementation Plan (3:29:08)

    Discussion regarding the Auditor-General's findings on the lack of a formal implementation plan for the National Suicide Prevention Strategy and the department's response.

  31. Family Law Cases and Suicide Data (3:31:57)

    Senator Whitten asks for data regarding the number of individuals involved in family law cases prior to suicide, focusing on spousal relationship problems as a factor.

  32. Implementation of Tick-Borne Disease Inquiry Recommendations (3:33:39)

    Senator Roberts questions the department on the progress of recommendations from the Senate inquiry into tick-borne diseases and the treatment of patients in Australia.

  33. Midwife Professional Indemnity Insurance for Homebirths (3:39:51)

    Senator Sharma discusses the upcoming expiry of the insurance exemption for midwives and the new government-underwritten product for endorsed midwives attending home births.

  34. TGA Medical Device Regulation and Assessments (3:53:31)

    The TGA explains its risk-based approach to medical device regulation, including the use of conformity assessments and reliance on overseas regulatory decisions.

  35. Australia's COVID-19 Vaccine Schedule and Sweden (4:03:02)

    Senator Roberts questions why Australia continues to prioritize mRNA vaccines while Sweden has shifted toward protein-based options like Novavax.

  36. Prescribing Hydroxychloroquine and Ivermectin for Influenza (4:12:17)

    A discussion on the restrictions placed on doctors prescribing hydroxychloroquine and ivermectin, focusing on medical ethics and evidence-based treatment.

  37. TGA Advertising Rules and Media Reporting (4:15:06)

    Senator Ruston raises concerns about new TGA guidance that classifies certain news reports as advertising, questioning potential impacts on media freedom.

  38. Mandatory Reporting and Medical Device Staffing (4:28:38)

    Officials discuss the implementation of mandatory reporting for medical device incidents and the staffing levels required for post-market surveillance.

  39. Pelvic Mesh Regulation and Device Classification (4:35:19)

    The committee examines the regulatory history of pelvic mesh and the TGA's move to reclassify surgical mesh products to a higher risk category.